Please select the option that best describes you:

How does the potential for a patient to accept or forego adjuvant tamoxifen factor into your recommendations on adjuvant RT for DCIS?  

Are there specific patient populations in which you may feel comfortable with a patient selecting only one adjuvant therapy approach (tamoxifen vs RT)? How do you help inform such a selection in patients who may be hesitant to receive both modalities?

For additional reading, see JCO OGR 11/2021 by @Laura Warren and @Jennifer R. Bellon reviewing landscape of adjuvant treatment after lumpectomy for DCIS, and companion study with longterm outcomes from RTOG 9804 (@Beryl McCormick et al). 



Answer from: Radiation Oncologist at Academic Institution
Comments
Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology
Now we can also consider/offer low dose/baby tamox...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more